Prev Arrow Stocks

Becton Dickinson and Company ($BDX) Stock Forecast: Down 5.0% Today

Morpher AI identified a bearish signal. The stock price may continue to fall based on the momentum of the negative news.

What is Becton Dickinson and Company?

Becton Dickinson (BDX) is a multinational medical technology company that specializes in the development and manufacture of medical devices, instrument systems, and reagents. The company is listed on the New York Stock Exchange (NYSE) under the ticker symbol BDX.

Why is Becton Dickinson and Company going down?

BDX stock is down 5.0% on May 2, 2025 18:15

  • The stock of Becton Dickinson (BDX) experienced a strong bearish movement.
  • The potential tariff impact on the company's profit outlook for 2025, coupled with a cut in EPS guidance due to tariff hits, likely contributed to the negative market sentiment.
  • Despite posting Q2 earnings that topped estimates, the missed revenue consensus and reduced EPS guidance may have overshadowed the positive earnings surprise, leading to the bearish trend.
  • The technical analysis suggesting a possible capitulation in BDX could have added to the selling pressure on the stock as investors reacted to the mixed financial performance and future outlook.

BDX Price Chart

BDX Technical Analysis

BDX News

This Apple Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Apple ( NASDAQ:AAPL ) , Airbnb ( NASDAQ:ABNB )

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Rosenblatt analyst Barton Crockett downgraded the rating for Apple Inc.

https://www.benzinga.com/25/05/45174776/this-apple-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-friday

0 News Article Image This Apple Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Apple  ( NASDAQ:AAPL ) , Airbnb  ( NASDAQ:ABNB )

Becton Dickinson ( BDX ) technical analysis - Becton Dickinson ( NYSE:BDX )

There may have been a capitulation in Beckton, Dickinson ( BDX ) yesterday. This could have bullish implications for the stock. Feel unsure about the market's next move? Copy trade alerts from Matt Maley-a Wall Street veteran who consistently finds profits in volatile markets.

https://www.benzinga.com/25/05/45167067/stock-of-the-day-bullish-capitulation-in-becton-dickinson

1 News Article Image Becton Dickinson  ( BDX )  technical analysis - Becton Dickinson  ( NYSE:BDX )

Potential Tariff Bites Into Becton Dickinson 2025 Profit Outlook, Company Will Invest $2.5 Billion To Boost US Manufacturing - Becton Dickinson ( NYSE:BDX )

BD posted Q1 adjusted EPS of $3.35, beating estimates; sales rose 4.5% to $5.27 billion but missed the $5.35 billion consensus. Fiscal 2025 EPS guidance cut to $14.06-$14.34 due to a $0.25 tariff hit; revenue outlook reaffirmed at $21.8 billion-$21.9 billion.

https://www.benzinga.com/general/health-care/25/05/45140102/potential-tariff-bites-into-becton-dickinson-2025-profit-outlook-company-will-invest-2-5-bill

2 News Article Image Potential Tariff Bites Into Becton Dickinson 2025 Profit Outlook, Company Will Invest $2.5 Billion To Boost US Manufacturing - Becton Dickinson  ( NYSE:BDX )

Becton Dickinson ( BDX ) Q2 Earnings Top Estimates

Becton Dickinson (BDX) delivered earnings and revenue surprises of 2.13% and 1.74%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

https://www.zacks.com/stock/news/2459793/becton-dickinson-bdx-q2-earnings-top-estimates

3 Missing News Article Image Becton Dickinson  ( BDX )  Q2 Earnings Top Estimates

Gear Up for Becton Dickinson ( BDX ) Q2 Earnings: Wall Street Estimates for Key Metrics

Besides Wall Street's top -and-bottom-line estimates for Becton Dickinson (BDX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.

https://www.zacks.com/stock/news/2456684/gear-up-for-becton-dickinson-bdx-q2-earnings-wall-street-estimates-for-key-metrics

4 Missing News Article Image Gear Up for Becton Dickinson  ( BDX )  Q2 Earnings: Wall Street Estimates for Key Metrics

Becton Dickinson and Company Price History

01.04.2025 - BDX Stock was down 10.3%

  • Despite delivering earnings and revenue surprises in Q2, Becton Dickinson (BDX) experienced a bearish movement in its stock.
  • Investors may have been anticipating stronger performance from the company, leading to a sell-off post earnings report.
  • The market's negative reaction to projections for key metrics suggests concerns about the company's future growth prospects.
  • Overall, the bearish movement in BDX could stem from profit-taking by investors expecting more robust results.

01.04.2025 - BDX Stock was down 14.7%

  • BDX posted strong Q1 adjusted EPS, surpassing expectations, but fell short of sales forecasts, causing a negative market response.
  • The company's commitment to invest $2.5 billion in enhancing US manufacturing raised concerns about potential cost increases and impacts on future profitability.
  • The reduction in fiscal 2025 EPS guidance, attributed to a $0.25 tariff impact, likely influenced investor sentiment negatively.
  • Despite outperforming expectations in Q2 earnings, adjustments in overall outlook and guidance appeared to dampen investor enthusiasm, leading to a decline in the stock price.

02.04.2025 - BDX Stock was down 5.0%

  • The stock of Becton Dickinson (BDX) experienced a strong bearish movement.
  • The potential tariff impact on the company's profit outlook for 2025, coupled with a cut in EPS guidance due to tariff hits, likely contributed to the negative market sentiment.
  • Despite posting Q2 earnings that topped estimates, the missed revenue consensus and reduced EPS guidance may have overshadowed the positive earnings surprise, leading to the bearish trend.
  • The technical analysis suggesting a possible capitulation in BDX could have added to the selling pressure on the stock as investors reacted to the mixed financial performance and future outlook.

02.04.2025 - BDX Stock was down 8.1%

  • BDX stock displayed bearish movement on the market recently.
  • Concerns about potential tariff impact on BDX's 2025 profit outlook, leading to a $0.25 decrease in EPS guidance, might have influenced the bearish sentiment.
  • Despite exceeding Q2 earnings expectations, BDX fell short of sales consensus and adjusted its EPS guidance, disappointing investors and driving the bearish trend.
  • Technical analysis hints at a possible capitulation in BDX, adding to the negative market sentiment and contributing to the stock's decline.

27.10.2024 - BDX Stock was down 1.0%

  • BDX experienced a bearish movement possibly due to the news of Embecta, a spinoff company, stopping its insulin patch pump program and planning restructuring.
  • Investors might be concerned about the implications of this decision on BDX's overall business strategy and potential impact on future revenue.
  • The positive news about Embecta's financial performance and stock jump could have diverted investor attention away from BDX, leading to a decline in BDX's stock price.
  • This unexpected development within the healthcare sector could have contributed to the bearish sentiment surrounding BDX today.

07.10.2024 - BDX Stock was down 5.0%

  • Despite strong fourth-quarter sales and exceeding revenue estimates, BDX faced a downturn likely attributed to concerns over lower sales expectations in China and market dynamics in the bioscience and pharma sectors.
  • The introduction of the BD IO Vascular Access System, designed for quick vascular access in critical care scenarios, did not offset the prevailing market sentiment towards the stock.
  • Investors may be evaluating BDX against other companies like MMSI, potentially leading to selling pressure on the stock.
  • Although positive earnings surprises were noted, they may not have been enough to counter broader market worries, contributing to BDX's bearish performance despite its robust financial results.

15.00.2025 - BDX Stock was down 1.7%

  • The bearish movement in BDX today could be attributed to profit-taking by investors after a period of strong gains or a negative development within the company itself.
  • The comparison with Alvotech (ALVO) might have highlighted potential outperformance by ALVO, leading investors to shift their focus and capital away from BDX.
  • Market sentiment towards medical stocks as a whole could have shifted, impacting BDX negatively despite its strong fundamentals.
  • It's essential for investors to closely monitor any updates regarding BDX's financial performance and strategic initiatives to make informed decisions in light of today's bearish movement.

06.01.2025 - BDX Stock was down 5.1%

  • BDX posted impressive Q1 earnings, surpassing revenue and EPS expectations, indicating a strong performance in the last quarter.
  • Despite the favorable earnings, the market responded negatively to BDX revising its forecast and revealing plans to split its Biosciences and Diagnostic Solutions business segments.
  • Investors may have apprehensions regarding the consequences of this strategic decision and its potential effects on future growth and profitability, influencing the bearish market trend seen in BDX today.

09.10.2023 - BDX Stock was down 5.5%

  • BDX reported Q4 earnings that decreased from last year and missed Street estimates, which could have contributed to the bearish movement.
  • The company's earnings totaled $108 million, which fell short of expectations.
  • Despite revenue topping estimates, BDX missed estimated earnings by 0.29%.
  • Becton, Dickinson also announced a dividend increase, but this news did not seem to offset the negative sentiment surrounding the earnings miss.

03.04.2024 - BDX Stock was down 0.5%

  • Despite reporting strong second-quarter sales and surpassing earnings and revenue estimates, BDX's stock experienced a bearish movement.
  • The overall bullish market sentiment did not positively impact BDX on Thursday, hinting at a specific factor affecting the stock.
  • Investors may have been concerned about future growth prospects or external factors despite the positive financial results.
  • The contrast between optimistic analyst outlook and market movement implies underlying issues influencing investor sentiment towards BDX.

03.05.2024 - BDX Stock was up 2.4%

  • BDX stock experienced a bullish movement after announcing the acquisition of Edwards Lifesciences' critical care business for $4.2 billion.
  • The market reacted positively to this strategic move, as it expands BDX's portfolio and strengthens its position in the healthcare industry.
  • The acquisition is seen as a smart investment by BDX to enhance its offerings and potentially drive future growth in the medical technology sector.
  • This news reflects investor confidence in BDX's strategic decisions and long-term prospects, contributing to the bullish movement in the stock price.

10.06.2024 - BDX Stock was up 0.1%

  • The bullish movement in BDX stock today could be attributed to the positive performance comparison with its competitors in the Health Care Equipment & Supplies industry.
  • Investors may be reacting favorably to the extensive industry analysis that highlights Boston Scientific's strong market standing, growth prospects, and key financial metrics.
  • The market may be optimistic about Boston Scientific's innovative products for medical procedures, such as angioplasty, cardiac rhythm management, and chronic pain treatment, which could drive future growth and profitability.
i
Disclaimer
Morpher is not liable for the content of the AI investment insights. Like most GPT-powered tools, these summaries may contain AI hallucinations and inaccurate information. Morpher is not presenting you with any investment advice. All investments involve risk, and the past performance of a security, industry, sector, market, or financial product does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. Such decisions should be based solely on an evaluation of their financial circumstances, investment objectives, risk tolerance, and liquidity needs. These summaries do not constitute investment advice.